Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Victoria's Secret & Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Victoria's Secret & Co trades at $78.4 (market cap $6.23B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.4× Victoria's Secret & Co's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | VSXY | |
|---|---|---|
Market Cap | $39.89B | $6.23B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $88.50 |
52-Week Low | $278.09 | $17.70 |
Enterprise Value | $38.15B | $8.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Victoria's Secret (VSXY) trades at $78.36, up 2.85% today, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals with support at $75 and resistance at $78. Fundamentally, the company maintains solid revenue around $6.2B with improving net margins, while international growth in China and Europe drives optimism. Analyst consensus is bullish with a $88.56 price target, supported by 55.6% buy ratings.
Outlook remains positive with international expansion and margin recovery as key catalysts, though risks include competitive pressures and execution challenges. The stock offers potential upside to analyst targets but requires monitoring of consumer spending trends and debt levels. Current valuation at P/E 31.22 appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
